# Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

> **NCT00663195** · PHASE4 · COMPLETED · sponsor: **Tottori University Hospital** · enrollment: 16 (actual)

## Conditions studied

- Chronic Stable Heart Failure

## Interventions

- **DRUG:** spironolactone + furosemide

## Key facts

- **NCT ID:** NCT00663195
- **Lead sponsor:** Tottori University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2008-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00663195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00663195, "Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00663195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*